Programmable and multi-targeted CARs: a new breakthrough in cancer CAR-T cell therapy

Tahmasebi, Safa; Elahi, Reza; Khosh, Elnaz; Esmaeilzadeh, Abdolreza

doi:10.1007/s12094-020-02490-9

Cited by 36 publications

(28 citation statements)

References 92 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TCZ inhibits downstream pro-inflammatory effects of IL-6 by binding to sIL-6R and mIL-6R and thus TCZ blocks both signaling and trans-signaling downstream pathways of IL-6 (62) . TCZ has received FDA approval to be used in rheumatologic diseases, such as Rheumatoid arthritis (63) , and has been studied to suppress the CAR T-induced cytokine storm in previous studies (64) . Several articles have investigated the injection of TCZ to the COVID-19 patients before and after ICU admission.…”

Section: Inhibition Of Il-6 In Covid-19mentioning

confidence: 99%

An updated overview of recent advances, challenges, and clinical considerations of IL-6 signaling blockade in severe coronavirus disease 2019 (COVID-19)

Elahi

Karami

Heidary

et al. 2022

International Immunopharmacology

View full text Add to dashboard Cite

show abstract

Section: Inhibition Of Il-6 In Covid-19mentioning

confidence: 99%

An updated overview of recent advances, challenges, and clinical considerations of IL-6 signaling blockade in severe coronavirus disease 2019 (COVID-19)

Elahi

Karami

Heidary

et al. 2022

International Immunopharmacology

View full text Add to dashboard Cite

show abstract

“…In the course of infection, SARS-CoV2 impairs the normal responses of the immune system [ 3 ], causing lymphopenia, granulocyte and monocyte abnormalities, increased antibodies, overactivation of T helper (Th) 1 and Th17 cells, dysregulation of regulatory T (Treg) cells, and overproduction of proinflammatory cytokines, especially in severe and critical cases. Disrupted control of the immune system increases the level of inflammatory cytokines, including interleukin (IL)-1β, IL-2, IL-6, IL-7, IL-8, IL-10, granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), interferon (IFN)-γ, tumor necrosis factor (TNF)-α, interferon gamma-induced protein 10 (IP-10), and monocyte chemoattractant protein 1 (MCP1) leading to cytokine storm, a common occurrence side effect in diseases treated by chimeric antigen receptor T (CAR-T) cells [ 4 , 5 ]. Cytokine storm is a causative phenomenon of hyper inflammation and respiratory system injury in SARS-CoV2 infection [ 6 , 7 ].…”

Section: Introductionmentioning

confidence: 99%

Nanocurcumin improves Treg cell responses in patients with mild and severe SARS-CoV2

et al. 2021

View full text Add to dashboard Cite

In Coronavirus disease 2019 (COVID-19), a decreased number of regulatory T (Treg) cells and their mediated factors lead to a hyperinflammatory state due to overactivation of the inflammatory cells and factors during the infection. In the current study, we evaluated the Nanocurcumin effects on the Treg cell population and corresponding factors in mild and severe COVID-19 patients. To investigate the Nanocurcumin effects, 80 COVID-19 patients (40 at the severe stage and 40 at the mild stage) were selected and classified into Nanocurcumin and placebo arms. In both the Nanocurcumin and placebo groups, the Treg cell frequency, the gene expression of Treg transcription factor forkhead box P3 (FoxP3), and cytokines (IL-10, IL-35, and TGF-β), as well as the serum levels of cytokines were measured before and after treatment. In both mild and severe COVID-19 patients, Nanocurcumin could considerably upregulate the frequency of Treg cells, the expression levels of FoxP3, IL-10, IL-35, and TGF-β, as well as the serum secretion levels of cytokines in the Nanocurcumin-treated group compared to the placebo group. The abovementioned factors were remarkably increased in the post-treatment with Nanocurcumin before pre-treatment conditions. By contrast, it has been observed no notable alterations in the placebo group. Our findings revealed the SinaCurcumin® effective function in a significant increase in the number of Treg cells and their mediated factors in the Nanocurcumin group than in the placebo group in both mild and severe patients. Hence, it would be an efficient therapeutic agent in rehabilitating COVID-19 infected patients.

show abstract

“…6,31 Cytokine storm or CRS is the most common inflammatory phenomenon that occurred in chimeric antigen receptor (CAR)-T-cell therapy of immune disorders, leading to tissue injury. [32][33][34] Targeting inflammatory immune cells and mediators in the course of COVID-19 infection would considerably mitigate the inflammation and augment the patients' recovery. 35,36 Hence, a better understanding of SARS-CoV-2 immunopathogenesis and the immune system responses can be beneficial in achieving appropriate treatments.…”

Section: Sars-cov-immunopathogenesismentioning

confidence: 99%

Recent advances in antibody‐based immunotherapy strategies for COVID‐19

Esmaeilzadeh

Rostami

Yeganeh

et al. 2021

J of Cellular Biochemistry

View full text Add to dashboard Cite

The emergence of a new acute respiratory syndrome Coronavirus 2 (SARS‐CoV‐2), the cause of the 2019‐nCOV disease (COVID‐19), has caused a pandemic and a global health crisis. Rapid human‐to‐human transmission, even from asymptomatic individuals, has led to the quick spread of the virus worldwide, causing a wide range of clinical manifestations from cold‐like symptoms to severe pneumonia, acute respiratory distress syndrome (ARDS), multiorgan injury, and even death. Therefore, using rapid and accurate diagnostic methods to identify the virus and subsequently select appropriate and effective treatments can help improvement of patients and control the pandemic. So far, various treatment regimens along with prophylactic vaccines have been developed to manage COVID‐19‐infected patients. Among these, antibody‐based therapies, including neutralizing antibodies (against different parts of the virus), polyclonal and monoclonal antibodies, plasma therapy, and high‐dose intravenous immunoglobulin (IVIG) have shown promising outcomes in accelerating and improving the treatment process of patients, avoiding the viral spreading widely, and managing the pandemic. In the current review paper, different types and applications of therapeutic antibodies in the COVID‐19 treatment are comprehensively discussed.

show abstract

Programmable and multi-targeted CARs: a new breakthrough in cancer CAR-T cell therapy

Cited by 36 publications

References 92 publications

An updated overview of recent advances, challenges, and clinical considerations of IL-6 signaling blockade in severe coronavirus disease 2019 (COVID-19)

An updated overview of recent advances, challenges, and clinical considerations of IL-6 signaling blockade in severe coronavirus disease 2019 (COVID-19)

Nanocurcumin improves Treg cell responses in patients with mild and severe SARS-CoV2

Recent advances in antibody‐based immunotherapy strategies for COVID‐19

Contact Info

Product

Resources

About